Novo CEO Doustdar 'Very Optimistic' About CagriSema
Source Bloomberg 财经1d ago
Summary
Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be ab…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Business
- Region
- Americas
- Language
- English
- Item ID
- business-42fcb093
Comments 0 comments
No comments yet. Be the first.